XML 38 R21.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases. The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer. The CODM evaluates financial information on a consolidated basis for the purposes of allocating resources and assessing performance. Substantially all of the Company's assets are located in the United States.
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
Year Ended December 31,
202520242023
Total revenues$376,072 $196,542 $59,606 
Less:
Cost of sales32,028 17,169 4,237 
Topical roflumilast program costs
10,938 5,210 35,607 
Topical JAK inhibitor program costs
741 2,945 3,334 
Other early-stage programs costs
6,372 11,477 5,681 
Research and development compensation and personnel-related expenses39,779 39,216 44,613 
Selling, general and administrative expenses274,033 228,908 184,628 
Other segment expenses(1)
24,408 20,014 22,607 
Total operating expenses388,299 324,939 300,707 
Operating loss(12,227)(128,397)(241,101)
Interest income
8,897 16,126 12,517 
Interest expense(12,083)(27,168)(29,712)
Other income (expense), net
443 47 (731)
Provision for income taxes1,171 647 3,113 
Segment and consolidated net loss$(16,141)$(140,039)$(262,140)
(1) Other segment expenses include professional services related to research and development, medical affairs, depreciation and amortization expenses.